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Dronedarone is an antiarrhythmic drug developed for
therapy of atrial ﬁbrillation (AF) that is structurally related
to amiodarone but has been the object of several molecu-
lar modiﬁcations in an attempt to reduce its toxicity
and improve its pharmacokinetic properties (1,2). The
most signiﬁcant structural changes are the removal of
iodine and the addition of a methane-sulfonyl group.
The removal of iodine should result in freedom from the
iodine-related organ toxicity of amiodarone, and the
second molecular change is thought to decrease lipo-
philicity, thus shortening the half-life of the drug and
reducing its accumulation in tissue. The compound shares
the class I to IV antiarrhythmic properties of amioda-
rone and has been explored for the treatment of a broad
range of patients with AF (3,4). In fact, more than 9,600See page 2376AF patients have been enrolled in randomized controlled
trials of dronedarone (5), which have conﬁrmed good toler-
ability and a lack of signiﬁcant proarrhythmic effects of
the compound. The ATHENA trial (A Trial With Drone-
darone to Prevent Hospitalization or Death in Patients With
Atrial Fibrillation) randomized patients with paroxysmal or
persistent AF to dronedarone or placebo and represents the
largest AF trial (4,628 patients) ever conducted with an
antiarrhythmic drug (6). It demonstrated a signiﬁcant reduc-
tion in cardiovascular-related hospital stays or death. Mainly
on the basis of the results of this trial, the drug was approved
by authorities in various jurisdictions and became part of
the algorithms of major guidelines for the treatment of AF
(7,8). Contraindications for the use of dronedarone were
based on the observations made in 2 large studies: The
ANDROMEDA study (Antiarrhythmic Trial with Drone-
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failure (and without a requirement that the patients have AF
at baseline) and the PALLAS trial (Permanent Atrial
ﬁbriLLAtion Outcome Study Using Dronedarone on Top of
Standard Therapy) (10) in patients with permanent AF (who
have never before been the focus of a prospective study using
antiarrhythmic drugs). Both of these trials had to be termi-
nated because of increased mortality and cardiovascular
events associated with dronedarone (9,10). In addition,
after drug approval, there were 2 reports about severe
hepatocellular liver injury in patients exposed to drone-
darone (11), which resulted in new regulatory labeling of
the drug that was more restrictive in Europe than in the
United States.
These diverging trial results and safety concerns led to
extensive debates about the clinical utility of dronedarone.
Today, more than 1 million patients have been exposed to
dronedarone worldwide, which probably reﬂects the need
for new antiarrhythmic drugs to treat the increasing number
of patients afﬂicted with symptomatic AF.
In this issue of the Journal, Friberg (12) reports data from
4,856 Swedish patients with symptomatic, nonpermanent
AF who were exposed to dronedarone. They were com-
pared with 170,139 control patients with AF who had
not received the drug during the period from May 2010 to
December 2012. The analyses were based on the previously
validated Swedish National Patient Register and the
Swedish Prescribed Drug Register. By linking these 2
registries, exposure times to dronedarone and other anti-
arrhythmic drugs were estimated and mortality/morbidity
data were calculated over a mean follow-up period of 1.6
years. Patients exposed to dronedarone were younger and
healthier than AF patients in the control group, had
tried more antiarrhythmic drugs previously, and more
often used anticoagulation therapy. There was an annual
mortality rate of 1.3% in dronedarone patients compared
with 14% in the control group. Even after adjustment for
many pertinent baseline variables and after propensity
score matching, mortality with dronedarone remained
lower than that of other AF patients (hazard ratio: 0.41;
95% conﬁdence interval: 0.33 to 0.51). The selection of
truly low-risk AF patients for therapy with dronedarone is
further indicated by a lower mortality than expected
from the general population (standardized mortality ratio:
0.67; 95% conﬁdence interval: 0.55 to 0.78). Finally,
the risk of severe liver disease was not increased in the
dronedarone group.
The results of this study need to be interpreted in the light
of the results of the aforementioned randomized clinical
trials, with special emphasis on 3 questions: Are the results
valid? What is the main message? What are the clinical
implications of the ﬁndings?
First, the results of the study appear valid. The analy-
ses are based on data from previously validated national
registries that included a large number of patients who
were treated with dronedarone according to current
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2386guidelines (7,8). More than 170,000 AF patients receiving
other often-used antiarrhythmic drugs served as a control
population. The data were analyzed by appropriate sta-
tistical methodology aimed at accounting for as many
confounders as possible, for instance, by performing
propensity score matching. Important limitations of the
data were addressed adequately. Among those, uncertainties
about discontinuation of dronedarone and hidden con-
founders that could not be corrected for are the most
important.
Second, there is a clear message provided to physicians
taking care of patients with AF. The main message is that
“dronedarone, as prescribed to AF patients in Sweden,
has not exposed patients to increased risks of death or
liver disease” (12). The author should be complimented
for undertaking the effort to pinpoint the safety of drone-
darone in everyday clinical practice when used according
to current recommendations (7,8). In this respect, these
“real-world” data are a valuable addition to those stem-
ming from the randomized controlled clinical trials,
particularly after the conclusion of a clinical drug devel-
opment program. In accordance with a previous meta-
analysis (13), the present ﬁndings put the mortality risk
of dronedarone in some perspective compared with that of
patients exposed to other antiarrhythmic drugs. Although
comparisons of survival rates with various drugs on the basis
of registry data are of somewhat limited value because of the
nonrandomized selection of patients, it is reassuring that
the survival rate of patients treated with dronedarone was,
at the very least, not inferior to rates observed in subjects
treated with sotalol or propafenone, that is, drugs that are
also administered predominantly to patients with preserved
left ventricular function.
Third, the present observations can be viewed as an
important endorsement of deﬁning the target population
for which there appears to be the most favorable risk-
beneﬁt ratio for dronedarone (7,8): Patients with non-
permanent AF who are younger, live an active life, and have
only little to moderate structural heart disease and hence
preserved left ventricular function. Although amiodarone is
clearly superior with respect to maintaining sinus rhythm
compared with dronedarone (14), amiodarone was associ-
ated with the worst survival rate in the present analysis, most
likely because amiodarone is usually reserved for therapy in
patients with advanced structural heart disease, but certainly
also because of its organ toxicity. It appears reasonable,
therefore, to use dronedarone in this population as a ﬁrst-
line drug, particularly because the compound has been
shown to reduce rates of AF-related hospital stays signiﬁ-
cantly in this population (6).
Finally, can we expect to see more data on dronedar-
one from controlled clinical trials? There is evidence from
the basic laboratory that the combination of low-dose
dronedarone and ranolazine, a drug originally developed as
an antianginal drug, signiﬁcantly improves the antiarrhythmicefﬁcacy of either drug alone (15). Currently, HARMONY
(A Study to Evaluate the Effect of Ranolazine and Dro-
nedarone When Given Alone and in Combination in
Patients With Paroxysmal Atrial Fibrillation) is evalu-
ating the clinical efﬁcacy of this combination in pacemaker
patients with AF (16). In summary, therefore, there is more
to learn about the ultimate role of dronedarone in treating
patients with AF, both from randomized controlled trials
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